Results from a VHIO-led study show that MYC targeting by Omomyc induces tumor DNA damage in patient-derived preclinical models of…
Peptomyc
The European Research Council (ERC) Proof of Concept (PoC) Grants provide funding to researchers who have previously received an ERC…
This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology…
Peptomyc, the VHIO and ICREA spin-off co-founded and directed by Dr. Laura Soucek, ICREA professor and director of the VHIO…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
The biotech company Peptomyc SL announced today that it has been awarded €5 million blended financing from the Horizon Europe,…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Published in the journal Genes & Development*, results of a study led by Laura Soucek, co-Director of the Vall d’Hebron…
Results of VHIO-led pharmacokinetic analysis of Omomyc, a therapeutic mini-protein that targets the MYC oncogene which is found deregulated in…
